Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Trocar Pharma Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is being reviewed by 1 distinct examiner, which indicates a highly concentrated prosecution profile. The company's current engagement with the USPTO is limited to this single point of review, suggesting a narrow or early-stage portfolio activity.
All current prosecution activity is situated within 1 distinct art unit. This means the technical evaluation of the company's claims is confined to one specific group of experts at the patent office. MARCOS L SZNAIDMAN is the busiest examiner for the portfolio, currently managing 1 pending office action. This single action constitutes the entirety of the company's pending workload at this time.
Because MARCOS L SZNAIDMAN is the only examiner with 1 pending office action, the company's immediate success in securing patent rights is tied to this specific relationship. The presence of only 1 distinct art unit further simplifies the prosecution landscape, as the company does not need to navigate the differing standards of multiple art units. This focused approach allows for a dedicated response strategy to the single outstanding action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996678 | RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996678 | RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME | SZNAIDMAN, MARCOS L | 1628 | §102§112DP | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrocar Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marcos L Sznaidman has the most, with 1 of Trocar Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
